MBCProject_4989_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- INTERFERON_ALPHA_RESPONSE+0.450
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.390
- INTERFERON_GAMMA_RESPONSE+0.300
- SPERMATOGENESIS+0.300
- INFLAMMATORY_RESPONSE+0.270
- MTORC1_SIGNALING+0.250
- MYC_TARGETS_V2+0.230
- IL6_JAK_STAT3_SIGNALING+0.220
Top 10 suppressed
- ADIPOGENESIS-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- BILE_ACID_METABOLISM-0.310
- HEME_METABOLISM-0.310
- FATTY_ACID_METABOLISM-0.280
- MYOGENESIS-0.240
- P53_PATHWAY-0.230
- NOTCH_SIGNALING-0.220
- ESTROGEN_RESPONSE_EARLY-0.210
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296100 | — | cohortA4 | 0.842 |
| 2 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.800 |
| 3 | BSR_09_0163_C1_S96 | — | C | 0.779 |
| 4 | a45a7511-4aa9-4d04-8f5f-34d12e4d5917 | — | — | 0.778 |
| 5 | BS_DHA5FMVW | ATRT | — | 0.766 |
| 6 | TCGA-85-7950-01A-11R-2187-07 | — | cohortSQ1 | 0.765 |
| 7 | SRR12475138 | — | — | 0.758 |
| 8 | MBCProject_4989_T2_RNA | — | C | 0.756 |
| 9 | BS_J1AB8PMA | medulloblastoma | — | 0.753 |
| 10 | SRR12475131 | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |